The proper way to inject simepaglutide is to choose a subcutaneous injection in the abdomen, upper arm, or thigh, once a week, or as directed by your doctor. Simelglutide is a newer hypoglycemic agent that can be used to control blood glucose in adults with type 2 diabetes mellitus, especially after dietary control and increased exercise, in patients with suboptimal glycemic control on metformin and/or sulfonylureas, and to reduce the risk of adverse cardiovascular events, such as nonfatal myocardial infarction and cardiovascular death, in patients with type 2 diabetes mellitus with concomitant cardiovascular disease. Injections of simethicone can be changed from the weekly dosing date, as long as the two doses are separated by at least 2 days (>48h), after which the weekly dosing can be continued. In the event of a missed injection, the dose may be administered as soon as possible within 5 days of the missed dose; if more than 5 days have elapsed, the missed dose needs to be skipped and the next dose continued on the normal dosing day. Any adjustments require a return to regular weekly dosing. The main adverse reactions to Simeglutide are hypoglycemia, nausea, diarrhea, and fatigue. It is contraindicated in patients with hypersensitivity to the components of the drug, previous or family history of medullary thyroid carcinoma, or type 2 multiple endocrine neoplasia syndrome. Patients who need to use Simeglutide are advised to strictly follow the doctor’s instructions and not to use the drug without authorization, so as not to cause adverse reactions.